US FDA Removes Minimum Efficacy Bar For COVID-19 Vaccines
Executive Summary
Instead of the 50% threshold, the FDA in updated guidance says that efficacy confidence intervals and point estimates should be ‘appropriately justified.’
You may also be interested in...
COVID Vaccines: XBB Strain Easy Call, But Disagreements Abound Between FDA, Advisors On Logistics
It took little convincing for FDA advisors to support changing COVID-19 vaccines to monovalent XBB formulations, but the committee still isn’t sold on the agency’s annual influenza-like campaign strategy for COVID vaccines and raised several harder calls that FDA and CDC will need to make including when to cut off bivalent shots use and who should get XBB.
Many US COVID-19 Guidances Set To Sunset With Emergency Declaration
But some, including some related to inspections and master protocols, will remain in effect to allow for revisions or a transition out of the pandemic posture.
COVID-19 Vaccine Strain Updates Don’t Exactly Fit Flu Model
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.